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Abstract: XPF endonuclease is one of the most important DNA repair proteins. Encoded by 
XPF/ERCC4, XPF provides the enzymatic activity of XPF-ERCC1 heterodimer, an endonuclease that 
incises at the 5’ side of various DNA lesions. XPF is essential for nucleotide excision repair (NER) 
and interstrand crosslink repair (ICLR). XPF/ERCC4 mutations are associated with several human 
diseases: Xeroderma Pigmentosum (XP), Segmental Progeria (XFE), Fanconi Anemia (FA), 
Cockayne Syndrome (CS), and XP/CS combined disease (XPCSCD). Most affected individuals are 
compound heterozygotes for XPF/ERCC4 mutations complicating the identification of 
genotype/phenotype correlations. We report a detailed overview of NER and ICLR functional 
studies in human XPF-KO (knock-out) isogenic cells expressing six disease-specific pathogenic XPF 
amino acid substitution mutations. Ultraviolet (UV) sensitivity and unscheduled DNA synthesis 
(UDS) assays provide the most reliable information to discern mutations associated with ICLR 
impairment from mutations related to NER deficiency, whereas recovery of RNA synthesis (RRS) 
assays results hint to a possible role of XPF in resolving R-loops. Our functional studies demonstrate 
that a defined cellular phenotype cannot be easily correlated to each XPF mutation. Substituted 
positions along XPF sequences are not predictive of cellular phenotype nor reflect a particular 
disease. Therefore, in addition to mutation type, allelic interactions, protein stability and 
intracellular distribution of mutant proteins may also contribute to alter DNA repair pathways 
balance leading to clinically distinct disorders. 
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1. Introduction 
The human XPF/ERCC4 gene is located in 16p13.1-p13.2 and encodes for the 916 amino acids 
long XPF protein, [1] which forms a stable heterodimer with ERCC1 in order to constitute a structure-
specific endonuclease that incises the 5’ side of several types of DNA lesions. XPF-ERCC1 
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heterodimer is essential for normal development, since the complete inactivation of the XPF/ERCC4 
or ERCC1 in humans and mice is incompatible with postnatal survival [2–5]. XPF is organized in 
three different domains (Figure 1A): an N-terminal helicase domain (residues 15–647), a central 
nuclease domain (residues 667–824) and a C-terminal helix-hairpin-helix (HhH) domain (residues 
848–916) [6]. XPF specifically recognizes single strand DNA (ssDNA) through its N-terminal helicase 
domain, while ERCC1 binds to double-strand DNA (dsDNA) through its hairpin region. This 
different substrate specificity allows the heterodimer to bind to both single and double-strand DNA 
and determines the incision position during DNA repair [7]. XPF/ERCC4 was originally identified as 
the defective gene in xeroderma pigmentosum complementation group F (XP-F) [8] since wild type 
XPF/ERCC4 cDNA complemented human XP-F cells as well as nucleotide-excision repair (NER) 
deficient Ercc4 and Ercc11 rodent cells [9]. XPF-ERCC1 dimer is able to establish temporal interactions 
with other proteins such as XPA, RPA and SLX4 to participate in several damage repair pathways 
[10–13]. The XPF-ERCC1 heterodimer participates in NER [8], interstrand crosslinks repair (ICLR) 
[14], microhomology-mediated end joining (MMEJ) [15], single strand annealing (SSA), a branch of 
double-strand breaks (DSB) repair, [15] and telomere maintenance [16]. Moreover, XPF-ERCC1 has 
been found to have possible backup roles in repairing oxidative damage and DNA breaks with 
damaged ends [17]. Additionally, it has emerged as a potential target for inhibitors to sensitize cancer 
cells to DNA damage-based chemotherapy [18,19]. Considering its wide involvement in DNA repair 
machinery, it is not surprising the range of human diseases associated with mutations in the 
XPF/ERCC4 and ERCC1 genes. 
Nucleotide-excision repair is one of the most versatile DNA damage repair pathways. It is 
involved in the removal of lesions caused by ultraviolet (UV) radiation like cyclobutane-pyrimidine 
dimers (CPDs) and 6–4 photoproducts (6–4 PPs), several natural and induced bulky chemical 
adducts, intrastrand crosslinks and ROS-generated cyclopurines. Many of these lesions distort the 
DNA double helix and must be removed to allow proper DNA replication and transcription [20]. 
NER is divided in two subpathways: global genome repair (GGR) and transcription-coupled repair 
(TCR), which differ in the damage recognition process but share the same mechanism to incise at 
both sides of the lesion, repair and ligate the DNA gap. In the GGR subpathway the entire genome is 
probed by the protein sensor XPC to check for damage, while TCR is activated when UV-induced 
lesions arrest the transcriptional machinery. When XPC recognizes the damage or RNA pol II stalls 
at the damage site, the transcription initiation factor IIH (TFHII) is recruited and XPD and XPB open 
the double helix. XPA verifies the damage and RPA occupies the non-damaged strand and help to 
recruit XPF-ERCC1 heterodimer to incise at 5′ of the damage. XPG then incises the 3′ side of the lesion 
producing a gap in the damaged strand of 22–30 nucleotides that is filled and sealed by DNA 
polymerases and ligase activities [20]. 
Several genome instability syndromes may arise if NER is compromised. One of them is 
xeroderma pigmentosum (XP; OMIM 278760), an autosomal recessive syndrome with 100% 
penetrance characterized by extreme photosensitivity and a 10,000-fold increased risk of skin cancers 
due to failure to repair DNA lesions produced by UV light [21]. Ocular abnormalities and increased 
risk of cancers of the oral cavity are also very common among the patients [22]. Eight XP 
complementation groups (XP-A to XP-G and XP-V) are described: proteins from XPA to XPG are 
involved in the repair of the UV lesions while XPV (pol η) is involved in bypassing DNA lesions by 
translesion DNA synthesis above the damaged nucleotides. Most XP-F patients have mild XP 
symptoms and a reduced level of nuclear XPF protein since most mutations promote XPF-ERCC1 
mislocalization to the cytoplasm of cells and lead to insufficient levels of XPF-ERCC1 to complete 
NER [23].  
Similar to XPD, which mutations can cause up to six different clinical phenotypes [24], 
XPF/ERCC4 mutations give raise to diseases other than XP. Mutation in XPF/ERCC4 can produce a 
progeria-like phenotype (XFE) characterized by the failure of the mutant XPF protein to properly 
translocate to the nucleus and to be recruited to sites of active DNA repair. The patients present severe 
photosensitivity, neurological and musculoskeletal abnormalities and hematopoietic symptoms 
[25,26]. XPF/ERCC4 mutations can produce Cockayne syndrome (CS), an autosomal recessive 
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disorder associated with a defective TCR [27,28]. CS patients show neurological and developmental 
abnormalities, growth and mental retardation, microcephaly, premature ageing and abnormal skin 
photosensitivity but that does not lead to skin cancer [29]. Some other rare XPF/ERCC4 variants can 
produce in the patients combined features of CS and XP. These cases present severe UV sensitivity 
and cancer predisposition typical of XP and developmental abnormalities which are common in CS 
patients [27,30]. 
One of the most dangerous DNA lesions are interstrand crosslinks (ICLs), since they block DNA 
strands separation thus inhibiting DNA replication, transcription and segregation [31]. ICLs can be 
produced as a result of cellular metabolism or by chemotherapeutic drugs such as mitomycin C 
(MMC), diepoxybutane (DEB), cisplatin, nitrogen mustard and psoralens [31]. The detection and 
repair of these lesions require a strict organization of multiple DNA repair proteins organized in the 
Fanconi anemia (FA)/Breast cancer (BRCA) DNA repair pathway [32]. Mutations in at least 22 genes 
involved in the FA/BRCA pathway cause FA, a rare genetic disease with an incidence of 1–9 in 
1,000,000 live births and an estimated carrier frequency of 1 in 250 in most populations. Its clinical 
features include bone marrow failure, pancytopenia, hyperpigmentation, skeletal malformations, 
small stature and urogenital abnormalities and predisposition to leukemias and solid tumors. FA 
cellular phenotype is characterized by extreme sensitivity to DNA cross-linking agents and 
chromosomal fragility [32,33]. 
FA proteins can be divided in three functional groups: the FANCore complex, the ID complex 
and the downstream proteins [32]. The FANCore complex is formed by seven FA proteins and six 
FA-associated proteins whose functions are to activate through monoubiquitination the heterodimer 
formed by FANCD2 and FANCI proteins (ID complex) to enable its relocation to the DNA damage 
site [34] where it allows the recruitment of SLX4-XPF-ERCC1 to incise and unhook the ICLs. Despite 
several other endonucleases being involved in ICLSs processing [12], the identification of FA patients 
carrying XPF/ERCC4 mutations suggests that XPF-ERCC1 endonuclease has a major role in ICL 
repair [35]. In accordance with these observations, in vitro models [6,36] and mice models [11,37] 
confirm XPF as the main endonuclease involved in the physiological unhook of ICLs. 
All XPF/ERCC4-mutated patients regardless their clinical phenotypes carry at least one allele 
with a missense mutation that does not affect dramatically its catalytic domain [21,27,35]. Taken 
together with the observation that mice homozygous for Ercc4 or Ercc1 null alleles are not viable, 
these data suggest that XPF-ERCC1 activity is essential for life. 
Geneticists have identified several missense mutations in XPF/ERCC4 associated with a distinct 
clinical phenotype (Figure 1A). Variant c.458G>C, p.Arg153Pro, was found in homozygosity in an 
XFE patient [25]. This amino acid change affects the helicase domain, a leucine-rich region involved 
in the interaction with SLX4 and DNA binding [6]. The patient’s main feature was the accelerated 
ageing phenotype and the disease was named as XFE progeroid syndrome [25]. Mutation c.689T>C, 
p.Leu230Pro was found in the paternal allele of an FA patient carrying a truncated maternal allele 
[35]. Mutation c.2065C>A, p.Arg689Ser was found in another FA patient along with another 
truncated allele and it was proven to affect XPF excision activity [35]. Variant c.706T>C, p.Cys236Arg 
was found in heterozygosity in two different patients: along with a frameshift mutation in the other 
allele caused CS [27], while in heterozygosity with the missense mutation c.1765C>T, p.Arg589Trp 
produced a CS/XP combined syndrome [27]. The c.1765C>T, p.Arg589Trp variant was previously 
shown to be associated with different XP clinical phenotypes: combined with a deletion in exon 3 of 
the second allele caused severe XP, while in heterozygosity with the missense mutation p.Arg799Trp 
caused mild XP [23,28,38]. The c.2395C>T, p.Arg799Trp missense mutation was found in 
homozygosis in a patient diagnosed with mild XP [39], but it was recently found along with a 
truncated allele in a patient with progeria syndrome [26]. 
Concerning the wide range of diseases associated with changes in XPF protein due to its crucial 
role in several DNA repair pathways, the objective of this study was to better understand the role of 
XPF in DNA repair and human disease by analyzing the genotype-phenotype correlation of 
XPF/ERCC4 pathogenic variants causing XP, FA, CS, XFE or CS/XP in a genetically homogeneous 
background. 
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2. Materials and Methods 
2.1. Cell Culture 
All the cell lines used in this study were cultured in DMEM (Dulbecco’s Modified Eagle 
Medium, Biowest cat. no. L0104, Barcelona, Spain) complemented with 10% FBS (Fetal Bovine Serum, 
Biowest cat. no. S181B) and 0.1 μg/mL Plasmocin (IBIAN Technologies, Zaragoza, Spain). Cells were 
cultured at a controlled temperature of 37 °C in 5% CO2 atmosphere. 
2.2. Generation of XPF-KO CELL Line 
XPF-KO cell line was generated by TALEN targeting ERCC4 exon 2 sequence: 5’ 
TCGCCGTGTAACAAATGAAATCACAAGCAACAGTCGCTATGAAGTTTACACA3’ (Underlined 
fragment represents TAL binding sites; central region represents FokI endonuclease cutting site) in 
HEK 293T (Human Embryonic Kidney 293T cells, ATCC CRL-11268). A reporter plasmid [40] 
containing the same ERCC4 recognition sequence, a red fluorescent protein sequence and an out of 
frame green fluorescent protein (GFP) that could be restored when the DSB produced by FokI was 
repaired by nonhomologous end joining (NHEJ) was also used. Then, 48 h post transfection double 
fluorescent (red and green) cells were selected by flow cytometry using the FACSAria II (BD 
Bioscience). Single cell cloning of these cells was performed by limit dilution in three 96-well plates. 
After 2 to 3 weeks, three individual clones were picked to check the lack of XPF protein by Western 
Blot (WB). 
2.3. Western Blot Analysis 
A total of 1 × 106 of cells were lysed in 50 μL of RIPA 1x lysis buffer (Millipore 20–188, Wien, 
Austria) with Benzonase nuclease (10 U/mL final) (VWR International 7074-6-3, Llinars del Vallés, 
Spain). Samples were incubated at 37 °C for 10 min and then centrifuged at 13,000 rpm. Total protein 
concentration of the supernatant was determined by Bio-Rad Protein Assay (Biorad, Hercules, CA, 
USA) according to manufacturer’s instructions and 50 μg of total proteins were denaturalized for 10 
min at 96° C in Laemmli 1x (Sigma S3401-10VL, Saint Louis, MO, USA) and loaded in an 8% SDS-
PAGE. Proteins were transferred to nitrocellulose membrane with the iBLOT2 (Invitrogen, Thermo 
Fisher Scientific, Waltham, MA, USA) apparatus following manufacturer’s guidelines. Membranes 
were blocked in 5% of milk in TTBS for 1 h at RT, and immunodetection was performed by incubating 
the membranes with diluted primary antibodies in blocking solution for 16 h at 4 °C. Primary 
antibodies used were: anti-XPF (mouse monoclonal, Ab-1 219 Thermo Fisher Scientific) 1:200 and 
anti-Actin (rabbit polyclonal, ab1801, Abcam, Cambridge, UK) 1:1000. The following day, membranes 
were incubated in secondary antibodies conjugated to peroxidase during 1 h at RT and revealed with 
Pierce ECL Western Blotting Substrate (Pierce). Digital images of the membranes were captured with 
a GeneGnome apparatus (Syngene Bio imaging, Bangalore, India). GeneTools analysis software 
(Syngene Bio imaging) was used to quantify the amount of protein per band. 
2.4. Characterization of the Selected XPF-KO Clone 
Genomic DNA was extracted from 5 × 106 clonal XPF-KO cells using the DNeasy Blood & Tissue 
Kit (Qiagen, Hilden, Germany) according to manufacturer’s instructions and DNA concentration was 
measured by spectrophotometry using NanoDrop ND-1000 (NanoDrop Technologies). PCR to 
identify mutations inserted by TALEN was performed using the following primers: For 
(TGTAGACTGGTTGGCTGAAGT) and Rev (CGCCTATGTGCTTCCCAAGA). DNA was amplified 
by denaturation at 94 °C for 30 s, annealing at 58 °C for 30 s, and elongation at 72 °C for 4 min for 35 
cycles. Subsequently, the target DNA was elongated at 72 ºC for 4 min. The product size was checked 
into a 1.5% agarose gel, the DNA band was purified and subcloned by TOPO TA cloning (Thermo 
Fisher Scientific), transformed in One Shot TOP10 Chemically Competent Escherichia coli cells (Life 
Technologies, Carlsbad, CA, USA), amplified by performing Minipreps with NucleoSpin Plasmid 
(Macherey-Nagel, Düren, Germany) and sent to Sanger sequencing at Macrogen Inc. (Seoul, Korea). 
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2.5. Generation of the XPF Mutant Variants 
HA tagged ERCC4 cDNA [35] was subcloned into a 3rd generation lentiviral vector pULTRA (a 
gift from Malcolm Moore (Addgene plasmid # 24129)) downstream of the EGFP-P2A site, to produce 
a bi-cistronic expression of EGFP and XPF. The ligation product was then transformed using One 
Shot Stbl3 Chemically competent E. coli (Thermo Fisher Scientific), amplified by standard Miniprep 
and Maxiprep procedures and sent to Sanger sequencing of Macrogen. 
Single nucleotide variants generated by site directed mutagenesis were: c.458G>C, 
p.(Arg153Pro); c.689T>C, p.(Leu230Pro); c.706T>C, p.(Cys236Arg); c.1765C>T p.(Arg589Trp); 
c.2065C>A, p.(Arg689Ser); and c.2395C>T, p.(Arg799Trp). The QuickChange II XL Site-Directed 
Mutagenesis Kit (Agilent Technologies) was used following manufacturers’ instructions to design 
mutagenic primers (https://www.genomics.agilent.com/primerDesignProgram.jsp) (Supplementary 
Table S1) to introduce the variants in the wild type (wt) cDNA of XPF. After PCR amplification, DpnI 
restricition enzyme was added for 1 h at 37 °C and the PCR product was transformed by XL10-Gold 
Ultracompetent Cells (Agilent Technologies), plated in LB Agar with Ampicilin (100 μg/mL). DNA 
from single colony minipreps was controlled by Sanger sequencing (Macrogen). 
2.6. Generation of the XPF Lentiviral Particles and Genetic Complementation of the XPF-KO Cells 
Production of lentiviral particle was achieved as in [41]. A total of 180,000 XPF-KO cells were 
seeded in a 12-well plate, then, 24 h later, cells were infected with 40 μL of each lentiviral particles 
and 1.5 μL Polybrene (Sigma). Three days after the infection, green fluorescence was detectable and 
cells that had integrated the virus with the XPF cDNA were selected by flow cytometry using the 
FACSAria II (BD Bioscience). 
2.7. Ultraviolet C Sensitivity Survival Assay 
XPF-KO cells expressing the different XPF variants were seeded in 2 mL of complete medium 
per duplicate in a 6-well plate. The, 24 h afterwards, medium was removed, cells were washed with 
PBS and UVC irradiated (254 nm; 15 W UVC Lamp G15-T18 Philips) at the doses of 0, 2, 5, 10 and 15 
J/m2. Complete medium was then added, and survival cells were counted after 72 h with a Beckman-
Coulter Cell Counter. At least three independent assays were performed, and results were expressed 
as a percentage of irradiated viable cells versus (vs) viability of the untreated controls. 
2.8. Unscheduled DNA Synthesis Assay  
A mix of poly-L and poly-D Lysine (Sigma-Aldrich) was used to coat 96-well plastic plates to 
improve cell attachment. A total of 8 × 104 cells of each transduced cell line were seeded in 100 μL of 
complete medium, seeding 10 replicate wells per cell line, from which half of them were UVC 
irradiated (254 nm) at 20 J/m2 after 16 h, while the other half remained as non-treated controls. After 
UV irradiation, cells were incubated in DMEM without FBS with 5-ethynyl-2′-deoxyuridine (EdU) 
(Invitrogen). After 2 h of incubation at 37 °C, cells were fixed in 100 μL of Fixation Buffer (300 mM 
Sucrose, 2% Formalin, 0.5% Triton X-100 and PBS) and incubated for 20 min on ice. EdU was detected 
by adding 41 μL/well of EdU Detection Solution (50 mM Tris-HCl pH 7.3, 4 mM CuSO4, 10 mM 
Sodium Ascorbate, 10 μM Alexa 488-conjugated azide, 20 ng/mL DAPI and H2O) for 1 h. Then, cells 
were washed in PBS 0.05% Tween-20 for 40 min, fixed with 100 μL Formalin/PBS (1:10) for 20 min 
and image acquisition and data processing achieved using a high content screening (HCS) system, 
the ARRAY SCAN VTI (Thermo Fisher Scientific). Plates were scanned with a CCD camera-equipped 
fluorescence microscope and the images were processed with the software Cellomics Scan (Thermo 
Fisher Scientific). At least three independent UDS assays were performed and results are represented 
as fluorescence intensity of treated and non-treated cells. 
2.9. Recovery of RNA Synthesis Assay  
Coating and seeding of the cells were performed as for the UDS assay. After 16 h, half of the cells 
were UVC irradiated (20 J/m2) and incubated for 8 h at 37 °C in DMEM with 1% FBS serum (to allow 
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recovery of RNA synthesis) before incubation during 2 h at 37 °C in 60 μL/well of serum-free DMEM 
supplemented with 5-ethynyluridine (EU) (100 μM). Detection and image acquisition were done as 
previously described. Detailed UDS and RRS methodologies can be found in [42]. 
2.10. Diepoxybutinate Sensitivity Survival Assay 
A total of 2 × 105 cells of each transduced line were seeded in 2 mL of complete medium per 
duplicate in a 6-well plate. Then, 24 h afterwards, DEB was added at a final concentration of 0, 0.025, 
0.05, 0.1 and 0.2 μg/mL. Cells were grown during the time needed by the untreated to perform at 
least three population doublings. Afterwards, cells were trypsinized and counted with a Beckman-
Coulter Cell Counter. At least three independent assays were performed, and results are expressed 
as a percentage of treated viable cells vs the untreated controls. 
2.11. Dieopxybutinate-Induced G2/M Cell Cycle Arrest 
A total of 1 × 106 cells of each cell line were seeded in 3 × 25 cm2 flasks (F25) in 5 mL of complete 
medium. Then, 24 h afterwards, DEB was added at doses of 0, 0.005, 0.01, 0.025 and 0.05 μg/mL. Then, 
48 h after the treatment, cells were trypsinized, PBS washed and resuspended in 200 μL of PBS. 2 mL 
of ice-cold ethanol 70% was added and cells were placed for 30 min on ice. Ethanol was removed by 
centrifugation and substituted with 2 mL of Staining solution (40 μg/mL Propidium Iodide, PI, 
Invitrogen, Carlsbad, CA, USA; Pure Link RNasa A 0.1 mg/mL, Invitrogen; PBS 1x). Cell cycle 
population distribution depending on DNA amount was analyzed by flow cytometry with 
FACSCalibur (BD Biosciences, Allschwil, Switzerland) as in [35]. A total of 15,000 events were 
registered per sample and data was analyzed by FlowJo VX software. 
2.12. Chromosome Fragility by the Flow Cytometric Micronucleus Test 
Around 3 × 105 cells from each cell line were seeded in 6-well plates. Then, 24 h later, they were 
untreated or treated with 0.01 μg/mL of DEB and kept in culture for enough time for at least one 
population doubling. Cells were then sequentially stained; first with ethidium monoazyde bromide 
(EMA) (0.025 mg/mL) and secondly with Sytox green (0.2 μM). EMA covalently binds to chromatin 
of dying and dead cells after a photo-activation step achieved by keeping cells under a 60 W light 
bulb (about 30 cm distance) for 20 min. Following this, cells were washed in cold PBS with 2% FBS. 
After that, a lysis step with 250 μL of lysis solution 1 (0.584 mg/mL NaCl, 1 mg/mL sodium citrate, 
0.3 μg/mL IGEPAL, 1 mg/mL RNase A and 0.2 μM Sytox green in deionized water) for 1 h at RT was 
done. Later, a second lysis step was done by adding 250 μL of solution lysis 2 (85.6 mg/mL sucrose, 
15 mg/mL citric acid and 0.2 μM Sytox green in deionized water) for 30 min at RT. After lysis, samples 
were stored at 4° C until being processed by flow cytometry (up to two days). Data acquisition was 
performed by flow cytometry with FACSCalibur; Sytox-associated fluorescence was detected by FL1 
channel while EMA-associated fluorescence was detected by FL3 channel. Collected data was 
analyzed by Flow Jo VX software. The data of micronuclei (MN) presented in this work represents 
results from five independent experiments each one in duplicate. 
3. Results and Discussion 
TALEN technology was used to edit the genome of HEK 293T cells to generate an XPF/ERCC4-/- 
human cell line (XPF-KO). The system included an RFP expressing plasmid (Surrogate plasmid) [40] 
with an out of frame GFP that could be restored when a DSB produced in the target recognition 
sequence in the XPF/ERCC4 gene was repaired by NHEJ. If TALEN proteins were functional, cells 
showed red and green fluorescence (Supplementary Figure S1A). After cell sorting and single cell 
cloning, clone number one was selected by Western blotting (WB) and sequence analysis 
(Supplementary Figure S1, panels B and C). Genetic complementation of the cellular phenotype of 
UV sensitivity with wild type XPF/ERCC4 cDNA definitely validated the XPF-KO clone 
(Supplementary Figure S1B, D). Genomic DNA analysis revealed that the mutations introduced by 
the TALEN in XPF/ERCC4 were two different deletions of 4 and 7 bp respectively: c.281_284del and 
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c.280_286del (Supplementary Figure S1C). Sequencing of the whole XPF/ERCC4 confirmed that the 
rest of the sequence remained unaltered. 
All the cDNAs of the different XPF/ERCC4 variants were transduced in the same conditions in 
XPF-KO, and all the XPF variant proteins were detectable by WB (Figure 1B). XPF-R799W showed 
levels of expression similar to wild type XPF (XPF-WT). XPF-R153P, XPF-L230P and XPF-R689S 
showed increased levels of protein production compared to XPF-WT. This was in contrast to the 
reduced levels observed in patients [25,26,35,39] but at the same time these levels of expression 
ensured that the cellular phenotype-genotype correlation depends only on the mutation and not on 
protein’s quantity. However, XPF-C236R and XPF-R589W showed decreased levels in vitro, similar 
to the levels observed in the patients [27,43], indicating that these XPF variants are inherently unstable 
independently of expression conditions and genetic backgrounds. 
 
Figure 1. (A) Schematic view of the XPF domains with the selected mutations and the diseases found 
in patients. The patient XPCSCD had an allele with C236R and the other with R589W. R799W 
mutation found in homozygosis in XP was also found in a cohort of patients with XFE sharing CS 
features. This figure was created with a protein designing software from [44]. XP: Xeroderma 
Pigmentosum; CS: Cockayne Syndrome; XPCSCD: Xeroderma Pigmentosum Cockayne Syndrome 
combined disease; XFE: Segmental Progeria. (B) Western Blot (WB) levels of each single XPF mutant 
transduced cell line. The two WB are split by spatial reasons. Levels of XPF proteins are normalized 
to GAPDH expression levels and expressed as a percentage relative to the exogenous XPF-Wt. 
GAPDH is used as a loading control. 
Cell lines expressing the different XPF variants were tested for sensitivity to UVC irradiation. 
For a better understanding, data were split into two different graphs: Figure 2A includes controls, 
XPF-R153P (XFE), XPF-L230P (FA) and XPF-R689S (FA) while the second graph (Figure 2B) shows 
controls, XPF-C236R (CS), XPF-R589W (CS/XP) and XPF-R799W (XP and XFE/CS). All the variants 
showed increased UVC sensitivity and cells expressing XPF-R153P and XPF-R589W were the most 
sensitive to UV, similar to XPF-KO (Figure 2A, B). These results are in concordance with the 
phenotype of the patients where these mutations were identified: XFE progeria patient showed skin 
photosensitivity and patient’s primary fibroblasts were 10 times more sensitive to UVC [25]. XPF-
R589W was found in XP patients and in an XP/CS patient XPCS1CD together with XPF-C236R variant 
[21,28]. Interestingly, another patient (CS1USAU) with XPF-C236R together with a XPF null allele 
p.Tyr577* had only the CS phenotype [27]. This could indicate that expression of XPF-R589W is 
actively causing the XP phenotype in patient XPCS1CD. In line with this hypothesis is the observation 
that, in our model and in [28], cells uniquely expressing XPF-C236R have mild UVC sensitivity 
(Figure 2B). A study performed by Popp and colleagues classifies for the first time XPF-R589W as an 
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FA mutation [43]. The patient from which it was identified was presented as an FA clinical 
phenotype, however, bone marrow failure, one of the crucial features to be classified as FA, was 
absent. Despite the atypical FA clinical phenotype, it was the first FA patient to develop skin 
photosensitivity. The second allele of XPF presented a novel splice site mutation (c.793-2A>G) which 
produced a premature termination of translation (p.Thr265Valfs*13), hence originating a null allele 
as happened with the previously reported FA XPF variants [35]. Contrary to Hashimoto group, who 
found the XPF-R589W mutation was abruptly affecting XPF structure and its SLX4 binding [45]. Popp 
and colleagues detected a residual proportion of XPF-R589W escaping from protein misfolding, able 
to reach the chromatin [43] as happened with the reported FA XPF variants. The two FA XPF variants, 
XPF-L230P and XPF-R689S, showed a marked resistance to UVC when compared to XPF-KO (Figure 
2A). These results confirmed previous studies which proved that these two mutations do not severely 
impair XPF to participate in NER of UVC-induced DNA lesions [35]. Interestingly, XPF-R589W 
mutant studied by [43] had reduced UVC irradiation resistance, and showed higher UVC irradiation 
resistance levels than XPF-L230P [43]. This combination of findings supports the conceptual premise 
that there is a link between ICL and NER pathways and endorse the theory that mutations found in 
specific locations of the sequence should not be associated with discrete DNA repair pathways 
impairment. 
XPF-R799W showed a mild sensitivity to UVC (Figure 2B). XPF-R799W was initially found in 
homozygosis in an XP patient with a mild phenotype (XP42RO) [39] but it was recently identified in 
heterozygosis with an early truncated XPF allele in a patient (CALIF1010) with CS and XFE features 
[26] and in heterozygosis with XPF-R589W in a patient (XP24BR) with XP and CS features [38]. 
Interestingly, XPF-R799W sensitivity to UVC is very similar to the sensitivity of the CS associated 
XPF-C236R variant (Figure 2B). This result provides an explanation to the XP phenotype of patient 
XP24BR [38] double mutant XPF-R589W/XPF-R799W: similar to patient XPCS1CD (see above), in 
patient XP24BR XPF-R799W allele would be responsible for the patient’s CS features while the XPF-
R589W allele would be responsible for the XP phenotype. These data also suggest a gene dosage 
dependent behavior for XPF-R799W: in homozygosis is associated to mild XP [39] while in 
heterozygosis with an allele with a deeply affected NER function it would be associated to atypical 
XFE and/or CS [26,38]. These data highlight the importance of mutated XPF alleles interactions to 
explain the variations of patients’ phenotypes. 
To further discern among XPF variants, functional analysis of GG-NER and TC-NER were 
performed with the whole set of variants. Figure 2C shows UDS assay data representing the DNA 
repair ability by measuring DNA synthesis in the G1 phase of the cell cycle after DNA damage 
induced by UVC. This assay allowed a clear distinction from the XPF mutations that conferred UV 
sensitivity and the FA mutations. Despite this, all the variants showed a certain grade of impairment 
in UDS, the two FA associated variants, XPF-L230P and XPF-R689S, retained around 30% to 40% of 
their UDS activities when compared to the XPF-WT cells (Figure 2C). XPF-R153P showed the lowest 
UDS value and the CS and the XP associated variants, XPF-C236R, XPF-R589W and XPF-R799W, 
showed UDS levels similar to the XPF-KO. These observations are in line with the UDS levels of the 
patients-derived cells bearing these mutations [21,23,26,27]. These results demonstrate that XFE, XP 
or CS associated mutations impair NER much more then FA related mutations, and that expression 
of XPF-C236R, XPF-R589W, and XPF-R799W can be more impairing for UDS than the complete 
absence of XPF. These results are also indicative that UDS levels as UVC sensitivity could be used to 
distinguish FA associated XPF mutations from NER impairing XPF variants. 
TC-NER capacity of our XPF mutants was evaluated by an RRS assay after UV induced damage: 
Figure 2D represents the ability of each cell line to synthetize RNA 8 h after UV damage in 
comparison with XPF-KO cells. All variants show a clear impairment of TC-NER including the FA 
associated XPF variants XPF-L230P and XPF-R689S. It has been observed that FA proteins, such as 
BRCA1, FANCD1, FANCD2, FANCA, and FANCM, are involved in resolving RNA-DNA hybrids 
known as R-loops. R-loops are structures formed when a nascent RNA hybridizes with the DNA 
template, leaving the non-template DNA single-stranded. R-loops are physiologically formed during 
transcription, but if they are not removed they can have deleterious effects on transcription, 
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replication and genome integrity [46,47]. These loops are produced when a replication fork collides 
with a transcriptional nascent mRNA. Furthermore R-loops are present in telomeres and contribute 
to telomere maintenance [46,47]. XPF plays a role in telomere maintenance as it is known to be 
involved in the excision of T-loops [16] and it is responsible for telomeres loss when TRF2 is 
overexpressed [48]. According to the low RRS levels showed, a hypothesis to explain the low RRS 
sustained by the FA-associated variant is that XPF could be another FA protein involved in R-loops 
removal and expression of these pathogenic variants could result in RRS impairment. This would be 
strongly in concordance with the study of Sollier and colleagues [49], who provided evidence that 
XPF would be involved in resolving R-loops when knocking down some RNA processing factors 
such as AQR [49]. The R-loops are known to block replication forks and Fanconi proteins such as 
FANCD2 or FANCA are important to avoid their accumulations during S-Phase [46,47], and XPF as 
a component of the FA/BRCA DNA repair pathway could have an active role in this process. These 
observations also question RRS assay as a useful tool to discern between XPF mutations associated 
to different syndromes. It has been recently put up for debate if RRS levels should be used as a 
determinant feature for CS classification of the patients which has driven to an enlargement of 
diagnosis criteria focusing more in their clinical features [50]. 
 
Figure 2. (A,B) Percentage of surviving cells after increasing doses of ultraviolet (UV) irradiation. 
Mean of at least two independent experiments of two replicates and the standard deviation is 
represented in the two graphs. (C) Unscheduled DNA synthesis (UDS) assay. Fluorescence intensity 
is represented relative to fluorescence intensity of Human Embryonic Kidney (HEK) XPF-KO. The 
graph represents the mean of at least three independent experiments with SD. (D) RRS assay. 
Fluorescence intensity is represented relative to fluorescence intensity of HEK XPF-KO. The graph 
represents the mean of at least three independent experiments with SD. 
The repair of ICLs that covalently bind the two strands of DNA is crucial for the survival of cells. 
The role of XPF as the main endonuclease involved in the excision of the damage caused by these 
crosslinks is well supported [6,11,35–37]. To test our XPF variants in the repair of DNA crosslinks, a 
DEB survival test was performed and all the XPF variants expressing cells showed a marked ICL 
sensitivity, resembling the one of cells lacking XPF (Figure 3A). XFE Progeria associated variant XPF-
R153P and XPF-R799W showed a strong sensitivity to DEB as already reported [25,26] such as the 
two FA associated mutants XPF-L230P and XPF-R689S [35] and the CS associated variant XPF-C236R, 
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[6]. It has been shown that a replication-independent repair (RIR) of DNA interstrand crosslinks exists 
and that it works outside the S-phase. This system depends on both branches of NER and translesion 
synthesis polymerases [51] and defects in this mechanism are additive with the defects in ICLs repair 
during the S-phase [52]. One hypothesis to explain DEB sensitivity even of the XPF variants that are 
not causing FA, could be their inability to participate in RIR. 
The accumulation of chromosome alterations caused by exposure to ICL agents is associated 
with a delay of the cell cycle to enter into mitotic phase. A DEB-induced G2/M cell cycle arrest assay 
was performed to test the different XPF variants. Again, for a better understanding of results, data 
have been plotted in two different graphs sharing the same controls (Figure 3B, C). All the XPF 
variants showed a higher percentage of G2/M arrested cells than the XPF-WT. The two FA associated 
mutations, XPF-L230P and XPF-R689S in concordance with previous studies [2,35] showed a marked 
G2/M block upon DEB treatment. Cells expressing progeria and CS associated mutation (XPF-R153P 
and XPF-C236R respectively) had very high levels of G2/M block, indicating that G2/M block after 
ICL treatment could be a useful additional tool for CS and XFE diagnosis. Regarding the remaining 
variants, XPF-R589W and XPF-R799W behaved as XPF-WT at the lowest DEB doses: XPF-R589W as 
expected from an XP associated variant would produce a more severe NER impairment than ICLR 
while XPF-R799W variant, associated to XP and XFE/CS features depending on the second allele, 
could have a minor impact on ICLR pathway when it is the only variant expressed in the cells. This 
will be in concordance with the observation, mentioned above, that when XPF-R799W is found in 
homozygosis patients suffer mild XP and not CS or FA. It would be interesting to generate cells 
expressing two different XPF mutated alleles to further our comprehension of genotype-phenotype 
interactions. 
 
Figure 3. (A) Percentage of surviving cells under increasing doses of diepoxybutane (DEB). The graph 
represents the mean of at least two independent experiments with two replicates and the SEM. (B,C) 
Percentage of cells stalled in G2/M phase after DEB exposition. Half of the XPF variants are 
represented in each graph with the positive and negative controls. Each graph represents the mean of 
at least two independent experiments with the SEM. (D) Micronuclei (MN) test after DEB (0.01 
μg/mL) exposure. Data is represented in fold changed vs. untreated cells. Graph represents the mean 
of at least three independent experiments with SD. 
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If left unrepaired, ICLs produce chromosome breaks that can result in MN detectable in 
daughter cells [53]. The flow cytometric MN test [54] provides useful information about the levels of 
chromosome breaks in a cell after ICL treatment by counting the number of MN in cycling cells 
(Figure 3D) by flow cytometry. The XPF-L230P expressing cell line showed the highest number of 
MN after DEB treatment, in concordance with the chromosome fragility phenotype of the FA patient 
in which it was identified [35]. The other FA associated mutation, XPF-R689S showed levels of MN 
similar to the XPF-KO (Figure 3D). XPF-R589W (XP) and XPF-R799W (XP, XFE/CS) variants also 
showed fragility levels resembling the ones of the XPF-KO cell line. Interestingly, R589W and R799W 
mutations showed high levels of MN, even if the percentages of G2/M arrested cells at this DEB dose 
were moderate (Figure 3C), indicating that the cells reach mitosis despite a heavy burden of 
chromosomal breaks thus implying a defect in the G2/M checkpoint. XPF-C236R, (CS), did not show 
chromosome fragility under DEB exposure, meaning that DNA damage is successfully resolved 
during the prolonged G2/M block (Figure 3C). The statistical error of XPF-R153P data was too large 
to reach any definitive conclusion. 
The functional studies performed in isogenic human cell lines of several XPF/ERCC4 missense 
variants enabled us to analyze if phenotypes are correlated with specific nucleotides changes or are 
influenced also by other factors. At first glance, it is remarkable how the position of the substitution 
along XPF/ERCC4 sequence does not reflect the disease: as illustrated in Figure 1A, four variants 
were confined in the helicase-like domain and two in the nuclease domain, but the patients’ 
phenotypes were not determined by these positions. Regarding the analysis of XPF activity in the 
NER pathway, UV sensitivity and UDS assays provided the most reliable information to discern 
mutations more associated to ICLR impairment such as L230P and R689S (Figure 2A-C). The RRS 
assay, did not contribute significantly to discern among the XPF phenotypes (Figure 2D) however, 
the unexpected low RRS levels of FA associated XPF variants could imply XPF is another FA protein 
involved in the resolving R-loops. Further studies are needed to confirm this hypothesis. 
Concerning ICLR analysis, there is a marked sensitivity of all variants and this combination of 
findings provides support for the conceptual premise that complete repair of ICLs requires S-phase 
dependent and S-phase independent DNA repair. Similar studies as the one performed in [52] with 
cells expressing the single XPF variants could be useful to find out if specific XPF mutations could be 
associated with one ICL DNA repair pathway or the other. 
The message that stands out from our studies is that, despite the cellular functional analyses 
sometimes provide promising suggestions to understand the genotype/phenotype interactions 
(Supplementary Figure S2), a defined cellular phenotype cannot be correlated to each XPF mutation; 
functional analysis might help, but definitive statements about the contribution of XPF variants to 
the phenotype must take in account other factors such as XPF levels of expression, cellular 
localization, allelic interactions and the different genetic background of each patient. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/S1, Supplementary Figure 
1: Generation and validation of the HEK XPF-KO clone, Supplementary Figure 2: Summary table of the whole 
set of XPF variants and their cellular phenotypes, Supplementary Table 1: Primers sequences used to introduce 
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